Please enable JavaScript to continue using this application.

Compare $AVTX vs $CADL | Chartloom

Compare

$AVTX vs $CADL

Avalo Therapeutics Inc · Candel Therapeutics Inc

AVTX

Avalo Therapeutics Inc

CADL

Candel Therapeutics Inc

Compare $AVTX vs $CADL

Comparing Avalo Therapeutics Inc and Candel Therapeutics Inc

AVTXAvalo Therapeutics Inc

CADLCandel Therapeutics Inc

AVTXAvalo Therapeutics Inc

Market cap

$722M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-86.6%

YTD performance

-19.8%

52W performance

-4.0%

FCF yield

-9.5%

CADLCandel Therapeutics Inc

Market cap

$728M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

82.7%

52W performance

57.8%

FCF yield

-7.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

AVTX

CADL

Detailed metrics comparison

AVTX

Avalo Therapeutics Inc

CADL

Candel Therapeutics Inc

Market Cap

AVTX$722M

CADL$728M

Enterprise Value

AVTX$639M

CADL$575M

Price

AVTX$13.65

CADL$9.94

P/E Ratio

AVTXN/A

CADLN/A

P/S Ratio

AVTX12,238.73x

CADL6,281.93x

EV/Sales

AVTX10,825.47x

CADL5,042.14x

EV/EBITDA

AVTX0.00x

CADL0.00x

P/B Ratio

AVTX1.79x

CADL6.18x

P/FCF Ratio

AVTXN/A

CADLN/A

EV/FCF

AVTX-9.35x

CADL-10.02x

PEG Ratio

AVTXN/A

CADLN/A

Forward P/E (NTM)

AVTXN/A

CADLN/A

Forward P/S (NTM)

AVTXN/A

CADLN/A

Revenue (TTM)

AVTX$59K

CADL$0

Revenue Growth (YoY)

AVTX-86.6%

CADLN/A

Forward Rev Growth

AVTX1345.1%

CADL371.1%

Gross Margin (TTM)

AVTX242.2%

CADL0.0%

Operating Margin (TTM)

AVTX0.0%

CADL0.0%

EBITDA Margin (TTM)

AVTX-154659.3%

CADL0.0%

Net Margin (TTM)

AVTX-170055.9%

CADL0.0%

FCF Margin (TTM)

AVTX-115745.8%

CADLN/A

Net Income (TTM)

AVTX$-100M

CADL$-89M

FCF (TTM)

AVTX$-68M

CADL$-57M

EPS (TTM)

AVTX-$2.30

CADL-$1.19

ROE (TTM)

AVTX-5803.0%

CADL-8938.0%

ROA (TTM)

AVTX-4822.0%

CADL-5631.0%

ROIC (TTM)

AVTX-5729.0%

CADL-6512.0%

Cash

AVTX$85M

CADL$202M

Debt

AVTX$2M

CADL$48M

Net Cash/Debt

AVTX$83M

CADL$154M

Current Ratio (TTM)

AVTX19.31x

CADL16.09x

Quick Ratio (TTM)

AVTX18.95x

CADL15.89x

Debt/Equity (TTM)

AVTX0.00x

CADL0.38x

Debt/Assets (TTM)

AVTX0.0%

CADL0.0%

Interest Coverage (TTM)

AVTXN/A

CADLN/A

Net Debt/EBITDA (TTM)

AVTX0.00x

CADL0.00x

Beta

AVTX0.62

CADL-0.28

52W Performance

AVTX-4.0%

CADL57.8%

YTD Performance

AVTX-19.8%

CADL82.7%

% from 52W High

AVTX-43.8%

CADL-29.0%

% from 52W Low

AVTX9.1%

CADL128.5%

Asset Turnover (TTM)

AVTX0.00x

CADL0.00x

FCF Yield (TTM)

AVTX-9.5%

CADL-7.9%

Earnings Yield (TTM)

AVTX-13.9%

CADL-12.2%

Dividend Yield (TTM)

AVTXN/A

CADLN/A

Rule of 40

AVTX-115,832.4

CADL0.0

EV/GP/RG

AVTX1.31

CADLN/A

Ticker research

View AVTX research View CADL research

Metric	AVTX Avalo Therapeutics Inc	CADL Candel Therapeutics Inc
Market & Valuation
Market Cap	$722M	$728M
Enterprise Value	$639M	$575M
Price	$13.65	$9.94
P/E Ratio	N/A	N/A
P/S Ratio	12,238.73x	6,281.93x
EV/Sales	10,825.47x	5,042.14x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.79x	6.18x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.35x	-10.02x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$59K	$0
Revenue Growth (YoY)	-86.6%	N/A
Forward Rev Growth	1345.1%	371.1%
Profitability
Gross Margin (TTM)	242.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-154659.3%	0.0%
Net Margin (TTM)	-170055.9%	0.0%
FCF Margin (TTM)	-115745.8%	N/A
Net Income (TTM)	$-100M	$-89M
FCF (TTM)	$-68M	$-57M
EPS (TTM)	-$2.30	-$1.19
ROE (TTM)	-5803.0%	-8938.0%
ROA (TTM)	-4822.0%	-5631.0%
ROIC (TTM)	-5729.0%	-6512.0%
Financial Health
Cash	$85M	$202M
Debt	$2M	$48M
Net Cash/Debt	$83M	$154M
Current Ratio (TTM)	19.31x	16.09x
Quick Ratio (TTM)	18.95x	15.89x
Debt/Equity (TTM)	0.00x	0.38x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	-0.28
52W Performance	-4.0%	57.8%
YTD Performance	-19.8%	82.7%
% from 52W High	-43.8%	-29.0%
% from 52W Low	9.1%	128.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-9.5%	-7.9%
Earnings Yield (TTM)	-13.9%	-12.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-115,832.4	0.0
EV/GP/RG	1.31	N/A
Ticker research	View AVTX research	View CADL research

Valuation

P/S Ratio

CADL

6,281.93x

AVTX

12,238.73x

EV/FCF

CADL

-10.02x

AVTX

-9.35x

Growth & revenue

Revenue Growth TTM

AVTX

-86.6%

Forward Revenue Growth

AVTX

1345.1%

CADL

371.1%

Profitability & performance

Gross Margin

AVTX

242.2%

CADL

0.0%

ROE

AVTX

-5803.0%

CADL

-8938.0%

FCF Yield %

CADL

-7.9%

AVTX

-9.5%

52-Week Performance

CADL

57.8%

AVTX

-4.0%

Detailed metrics comparison

AVTX

Avalo Therapeutics Inc

CADL

Candel Therapeutics Inc

Market Cap

AVTX$722M

CADL$728M

Enterprise Value

AVTX$639M

CADL$575M

Price

AVTX$13.65

CADL$9.94

P/E Ratio

AVTXN/A

CADLN/A

P/S Ratio

AVTX12,238.73x

CADL6,281.93x

EV/Sales

AVTX10,825.47x

CADL5,042.14x

EV/EBITDA

AVTX0.00x

CADL0.00x

P/B Ratio

AVTX1.79x

CADL6.18x

P/FCF Ratio

AVTXN/A

CADLN/A

EV/FCF

AVTX-9.35x

CADL-10.02x

PEG Ratio

AVTXN/A

CADLN/A

Forward P/E (NTM)

AVTXN/A

CADLN/A

Forward P/S (NTM)

AVTXN/A

CADLN/A

Revenue (TTM)

AVTX$59K

CADL$0

Revenue Growth (YoY)

AVTX-86.6%

CADLN/A

Forward Rev Growth

AVTX1345.1%

CADL371.1%

Gross Margin (TTM)

AVTX242.2%

CADL0.0%

Operating Margin (TTM)

AVTX0.0%

CADL0.0%

EBITDA Margin (TTM)

AVTX-154659.3%

CADL0.0%

Net Margin (TTM)

AVTX-170055.9%

CADL0.0%

FCF Margin (TTM)

AVTX-115745.8%

CADLN/A

Net Income (TTM)

AVTX$-100M

CADL$-89M

FCF (TTM)

AVTX$-68M

CADL$-57M

EPS (TTM)

AVTX-$2.30

CADL-$1.19

ROE (TTM)

AVTX-5803.0%

CADL-8938.0%

ROA (TTM)

AVTX-4822.0%

CADL-5631.0%

ROIC (TTM)

AVTX-5729.0%

CADL-6512.0%

Cash

AVTX$85M

CADL$202M

Debt

AVTX$2M

CADL$48M

Net Cash/Debt

AVTX$83M

CADL$154M

Current Ratio (TTM)

AVTX19.31x

CADL16.09x

Quick Ratio (TTM)

AVTX18.95x

CADL15.89x

Debt/Equity (TTM)

AVTX0.00x

CADL0.38x

Debt/Assets (TTM)

AVTX0.0%

CADL0.0%

Interest Coverage (TTM)

AVTXN/A

CADLN/A

Net Debt/EBITDA (TTM)

AVTX0.00x

CADL0.00x

Beta

AVTX0.62

CADL-0.28

52W Performance

AVTX-4.0%

CADL57.8%

YTD Performance

AVTX-19.8%

CADL82.7%

% from 52W High

AVTX-43.8%

CADL-29.0%

% from 52W Low

AVTX9.1%

CADL128.5%

Asset Turnover (TTM)

AVTX0.00x

CADL0.00x

FCF Yield (TTM)

AVTX-9.5%

CADL-7.9%

Earnings Yield (TTM)

AVTX-13.9%

CADL-12.2%

Dividend Yield (TTM)

AVTXN/A

CADLN/A

Rule of 40

AVTX-115,832.4

CADL0.0

EV/GP/RG

AVTX1.31

CADLN/A

Ticker research

View AVTX research View CADL research

Metric	AVTX Avalo Therapeutics Inc	CADL Candel Therapeutics Inc
Market & Valuation
Market Cap	$722M	$728M
Enterprise Value	$639M	$575M
Price	$13.65	$9.94
P/E Ratio	N/A	N/A
P/S Ratio	12,238.73x	6,281.93x
EV/Sales	10,825.47x	5,042.14x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.79x	6.18x
P/FCF Ratio	N/A	N/A
EV/FCF	-9.35x	-10.02x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$59K	$0
Revenue Growth (YoY)	-86.6%	N/A
Forward Rev Growth	1345.1%	371.1%
Profitability
Gross Margin (TTM)	242.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-154659.3%	0.0%
Net Margin (TTM)	-170055.9%	0.0%
FCF Margin (TTM)	-115745.8%	N/A
Net Income (TTM)	$-100M	$-89M
FCF (TTM)	$-68M	$-57M
EPS (TTM)	-$2.30	-$1.19
ROE (TTM)	-5803.0%	-8938.0%
ROA (TTM)	-4822.0%	-5631.0%
ROIC (TTM)	-5729.0%	-6512.0%
Financial Health
Cash	$85M	$202M
Debt	$2M	$48M
Net Cash/Debt	$83M	$154M
Current Ratio (TTM)	19.31x	16.09x
Quick Ratio (TTM)	18.95x	15.89x
Debt/Equity (TTM)	0.00x	0.38x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.62	-0.28
52W Performance	-4.0%	57.8%
YTD Performance	-19.8%	82.7%
% from 52W High	-43.8%	-29.0%
% from 52W Low	9.1%	128.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-9.5%	-7.9%
Earnings Yield (TTM)	-13.9%	-12.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-115,832.4	0.0
EV/GP/RG	1.31	N/A
Ticker research	View AVTX research	View CADL research